We are live on ! Find out more

Ligand Pharmaceuticals

LGND

Market cap $5.52B

276.98 USD

-3.67

1.31%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

277.00

+0.02

0.01%

1 day

-1.31%

5 days

-3.84%

1 month

-5.07%

3 months

9.37%

6 months

33.29%

Year to date

45.69%

1 year

67.34%

5 years

226.82%

10 years

285.82%

About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Employees: 47

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 21.4%

Neutral 78.6%

Negative 0%

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand to Participate in September Investor Conferences

JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.

Ligand to Participate in September Investor Conferences

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Investors Business Daily

Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter

Ligand stock slipped early Thursday after the royalty powerhouse reported better-than-expected earnings and sales.

Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter

Investors Business Daily

This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.

This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

XOMA Royalty Announces Closing of Its Acquisition by Ligand

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.

XOMA Royalty Announces Closing of Its Acquisition by Ligand

3 Overlooked Stocks Positioned for the Next Market Rotation

Tech has carried this market for years, but it isn't the only game left running. Small caps are outperforming in 2026, the Magnificent Seven have cooled, and money is starting to spread into corners of the market that retail investors rarely check.

3 Overlooked Stocks Positioned for the Next Market Rotation

See News Rankings

Price charts implemented using Lightweight Charts™